Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA)

8 novembre 2026 mis à jour par: Prof. Jan Martinek, MD, PhD, AGAF, Institute for Clinical and Experimental Medicine

A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA Trial)

Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. The investigators plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Trnava, Slovaquie, 91701
        • Pas encore de recrutement
        • University Hospital Trnava
        • Contact:
          • Rastislav Husťak, MD
          • Numéro de téléphone: +421 33/593 81 11
          • E-mail: rhustak@gmail.com
        • Contact:
    • Slovakia
      • Martin, Slovakia, Slovaquie, 03601
        • Recrutement
        • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin,
        • Contact:
        • Contact:
          • Peter Banovcin, Ass. Profesor
          • Numéro de téléphone: +421 4203 448
          • E-mail: pbanovcin@gmail.com
      • Brno, Tchéquie, 60200
        • Recrutement
        • St. Anne's University Hospital Brno, Czech Republic
        • Contact:
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
  2. Refractory (> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
  3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
  4. Endoluminal planimetry: EGJ-DI < 3 mm2/mmHg (with 40ml)
  5. Age above 18 years
  6. Signed informed consent form

Exclusion Criteria:

  1. No previous attempt with at least one prokinetic drug
  2. Previous esophageal myotomy (open, laparoscopic or endoscopic)
  3. Primary esophageal motility disorder (achalasia etc.)
  4. Active erosive esophagitis
  5. Active peptic ulcer disease
  6. Esophageal stricture (peptic, malignant, other)
  7. Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
  8. Known eosinophilic esophagitis
  9. Severe coagulopathy
  10. Esophageal or gastric varices
  11. Advanced liver cirrhosis (Child B or Child C)
  12. Pregnancy or puerperium
  13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
  14. Any other condition, which in the opinion of the investigator would interfere with study requirements
  15. Known gastroparesis

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: POEM arm

Patients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia

All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Efficacy POEM in patients with postfundoplication dysfagia
Délai: 6 months

The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months

6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Eckardt score
Délai: At baseline, 3, 6 and 12 months

The Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12

At baseline, 3, 6 and 12 months
Mellow - Pinkas score
Délai: At baseline, 3, 6 and 12 months

The Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only)

At baseline, 3, 6 and 12 months
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)
Délai: At baseline, 3, 6 and 12 months

The PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life.

At baseline, 3, 6 and 12 months
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)
Délai: At baseline, 3, 6 and 12 months

The GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75.

At baseline, 3, 6 and 12 months
Integrated Relaxation Pressure (IRP)
Délai: At baseline, at 6 months

High resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value >15 mmHg indicates EGJ outflow obstruction.

At baseline, at 6 months
Endoluminal planimetry (Endoflip)
Délai: At baseline, ať 6 months

Pyloric distensibility measured by impedance planimetry (EndoFLIP device)

At baseline, ať 6 months
Esophagogram
Délai: At baseline, at 6 months

Esophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying.

Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes.

At baseline, at 6 months
Eckardt score
Délai: At baseline, 3 and 12 months

The Eckardt score is used to assess the severity of achalasia symptoms. It is based on the four main symptoms of achalasia: dysphagia, regurgitation, chest pain and weight loss. Each symptom has four levels of severity: none = 0 point, occasional = 1 point, daily = 2 points, each meal = 3 points. The sum of the points gives the final score. Final score scale: 0 (best) - 12 (worst). Treatment success is defined as a decrease of Eckardt score by at least 1 point and an overall Eckardt score ≤ 2.

At baseline, 3 and 12 months
GERD
Délai: At baseline, 3, 6 and 12 months

Presence of reflux esophagitis based on endoscopy findings.

At baseline, 3, 6 and 12 months
Esophageal 24h-Hour pH metry
Délai: At 3 months after procedure

An esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After

At 3 months after procedure
PPI/H2 antagonists
Délai: At baseline, 3, 6 and 12 months

PPI's and/or H2 antagonists use before and after procedure (POEM).

At baseline, 3, 6 and 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2025

Achèvement primaire (Estimé)

1 juin 2027

Achèvement de l'étude (Estimé)

1 juin 2027

Dates d'inscription aux études

Première soumission

10 février 2025

Première soumission répondant aux critères de contrôle qualité

6 mars 2025

Première publication (Réel)

12 mars 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner